DocGo Inc. (DCGO) Earnings Call Transcript & Summary

August 7, 2024

NASDAQ US Health Care Health Care Providers and Services earnings 53 min

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thanks, operator. Ahead of handing things over to management, I'd like to offer a few comments about forward-looking statements. Everything said on this conference call that isn't a historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar words might be employed to flag those forward-looking statements; such statements don't promise future performance, and we can't guarantee that our plans, intentions, outcomes, results, or expectations will be achieved or realized. By their nature, forward-looking statements carry substantial risks, uncertainties, and assumptions, a great many of which lie outside our control and could lead our actual results or outcomes, or when results or outcomes occur, to differ materially from what our forward-looking statements contain. Among these risks, uncertainties, and assumptions are those covered in our risk factors and other sections of DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, and additional reports and statements DocGo has filed with the SEC, to which we point your attention, though that list isn't exhaustive. What actually happens and what we actually achieve, or the timing of those results or outcomes, might differ materially from what these forward-looking statements express or imply. Today's call also cites non-GAAP financial measures. You'll find reconciliations of those non-GAAP financial measures against the most directly comparable GAAP financial measures given directly during this call, or in our earnings release, or in the current report on Form 8-K containing our earnings release, which appears on our website, docgo.com, and has been filed with the SEC. What's shared on this call holds true only as of the date under discussion. Investors shouldn't presume statements stay relevant and in effect afterward. We're under no duty to refresh any information covered on this call to account for events or circumstances arising after today's date, or to account for new information or unanticipated events, unless the law requires it. Right now, I'm happy to pass the call to Mr. Lee Bienstock, DocGo's CEO. Lee, the floor is yours.

Lee Bienstock

executive
#2

Thanks, Mike, and I appreciate everyone being here today. Our second-quarter results were outstanding, with revenue of $164.9 million and Adjusted EBITDA of $17.2 million, powered by solid operational execution, and we simultaneously achieved meaningful advances in new business development and cash collections. A great deal of momentum is moving through the sales pipeline. At the start of this year, we kicked off an effort aimed specifically at engaging in conversations with prospective partners throughout our three customer verticals, along with partnership possibilities involving virtual-only providers seeking to leverage our in-person capability as a complement to what they offer. Without question, the healthcare sector is progressively seeking mobile delivery solutions that broaden access to care while bringing costs down. Telemedicine offers many benefits, yet by itself it comes with considerable constraints. What we're discussing with these potential strategic partners centers on DocGo's distinctive capacity to provide last-mile physical care. This initiative is producing solid results, with multiple new relationships now in the contracting stage and others advancing through the sales pipeline. I'm genuinely eager to tell you about those opportunities once they develop further. I'm also extremely proud of how we executed operationally in Q2; winding down the downstate migrant-related locations under our HPD contract was a major undertaking, yet we accomplished it without disruption, and at the same time we started rightsizing our cost structure to match. In my view, we handled this process remarkably well, and we anticipate margin gains ahead as those rightsizing efforts take effect; we likewise achieved considerable progress on cash collections during the quarter. Cash flow from operations came in above $35 million in Q2 of 2024, lifting our cash balance by over $25 million compared with the close of Q1. It's worth pointing out, I believe, that the cash balance also accounts for the roughly $5 million of DocGo shares we bought back during the period and close to $10 million since the beginning of 2024. We keep collaborating with our large municipal customers in an effort to normalize how payments are processed, and we anticipate sustained robust cash flow from operations across the quarters ahead. We expect that will provide the resources to further reinforce our balance sheet, fund possible additional stock repurchases, and, naturally, keep fueling the strong growth we forecast going forward. Consequently, we are raising our guidance for cash flow from operations from $70 million-$80 million to a revised range of $80 million-$90 million for 2024. We additionally announced the creation of a world-class Medical Advisory Board, featuring a distinguished collection of physicians and specialists from top national institutions. This advisory board will provide guidance and expertise regarding our clinical offerings and will publish medical research examining how the company's programs affect patient outcomes. We're thrilled to draw on their expertise as we keep creating innovative healthcare solutions for the people who need them most. Like I typically do, I'd like to take a moment now to walk through our three main customer verticals: payers and providers, hospital systems, and municipal population health. Within our payer and provider vertical, we've recently seen a burst of contract wins, and a number of those opportunities have significant potential to expand down the road. A key leading indicator for this vertical is how many patients DocGo has been assigned for care gap closure services, and that figure has more than doubled quarter over quarter, with Q2 coming in above Q1. These programs are delivering strong results, and the ROI for customers is growing more and more evident. To illustrate, one customer has seen a 50% drop in all-cause readmissions among complex patients who receive our care after discharge. Beyond that, our quality measure and care gap closure programs let payers keep or boost their quality ratings, which can meaningfully affect payer financials. In Q2, we brought on a top ten payer in Southern California, and there are plans to expand with that same customer into New York. Our hospital system work keeps performing well. We picked up new medical transport wins in New York and Delaware, along with key extensions in New Jersey and the UK. On the whole, revenue growth so far in 2024 came to 13% versus the first half of 2023, and we continue to expect medical transportation to grow around 15% or more annually in the near term. We're in the last stages of contracting with one of New Jersey's largest hospital networks for a mobile health program delivering physicals and wellness checks to their enterprise customers throughout the state. We're also seeing growing interest from major health systems in our transitional care management mobile health offerings, remote patient monitoring, virtual care management, and readmission reductions, among other things, all built to help patients stay healthy at home and out of the hospital. In our municipal population health vertical, we just launched our first mobile X-ray program for the City of New York, and we're planning seasonal vaccination programs for clients in Texas, New York, and Washington, D.C. We also won a project from the State of New Mexico to deliver nursing care and mobile vaccination clinics, nursing call centers statewide, and behavioral health services for the New Mexico Behavioral Health Institute. On top of that, we won a contract to supply X-ray technicians at multiple sites for a new customer in Arizona. Finally, we take pride in the deep clinical expertise and mobile healthcare services we've delivered through the humanitarian response in New York. In Q2 by itself, our clinicians facilitated over nearly 200,000 patient interactions across these programs, including 150,000 behavioral health encounters and nearly 50,000 medical encounters, among them over 42,000 for intake and triage, 8,000 vaccinations, and 2,600 QuantiFERON blood tests. Everything we're doing aligns with the municipal work we've done historically, delivering care to vulnerable patients through a range of public health programs serving many groups — people without insurance, the LGBTQ+ community, homeless populations whether in shelters or on the streets, and asylum seekers who have recently arrived, all outside standard medical facilities. As a group, our performance matches the guidance we shared in last quarter's earnings release, and we're reaffirming our 2024 guidance: $600 million-$650 million in revenue and $65 million-$75 million in Adjusted EBITDA, while lifting our expectation for cash flow from operations to $80 million-$90 million, up from $70 million-$80 million. On top of that, we still anticipate that revenues from our base business will deliver strong sequential growth in the second half of 2024 and come in at approximately $400 million in 2025. Let me repeat that the 2025 revenue expectation for our base business is not overall revenue guidance for 2025, since we expect some migrant-related revenues next year. One of the most significant takeaways from the quarter, I believe, would be both the quality and the quantity of new opportunities coming into the pipeline. As we coordinate with New York City to taper down migrant-related work, that has opened up considerable bandwidth for pursuing other opportunities. Some of these opportunities, as I said, are maturing toward the contracting phase, and I expect multiple new programs to launch in the second half of 2024; this will directly complement our traditional RFP channel and give us another conduit for growth. Ultimately, we possess the technology, logistical infrastructure, and balance sheet needed to offer large-scale, last-mile deployments alongside national healthcare providers, payers, hospitals, and municipalities. Pair that with the very broad scope of clinical services DocGo provides, and we believe our strategic position going forward is excellent. I'll now turn the call over to Norm to cover the financials. Norm, please go ahead.

Norman Rosenberg

executive
#3

Thanks, Lee, and good afternoon everyone. For the second quarter of 2024, total revenue came in at $164.9 million, which represents a 31% rise over the second quarter of 2023. Mobile health revenue during the second quarter of 2024 reached $116.7 million, marking a 46% gain versus the second quarter of 2023. Growth showed up across a number of projects, business lines, and geographies. That said, most of the year-over-year revenue improvement came from the migrant-related projects we ran in New York for both HPD and H+H. As we told you on our prior earnings call, those migrant-related revenues fell sequentially in Q2, which mirrors the wind down of certain sites in New York City that started in mid-May; we expect these migrant-related revenues to keep declining sequentially throughout the remainder of 2024. Transportation services revenue rose to $48.2 million in Q2 of 2024, which was 6% above the transport revenues we posted in the second quarter of 2023. Our three biggest markets — New York, Pennsylvania, and the U.K. — produced the largest gains; during the second quarter, mobile health revenues made up roughly 71% of total revenues, while transport contributed the other 29%. Net income reached $5.9 million in Q2 of 2024, versus net income of $1.3 million in the second quarter of 2023. That higher net income stems from greater revenues and wider margins. Adjusted EBITDA for the second quarter of 2024 totaled $17.2 million, an increase from $9.1 million in last year's second quarter. Adjusted EBITDA margin came to 10.4% in Q2, rising from 7.3% in the second quarter of 2023. That marked the third quarter in a row of double-digit adjusted EBITDA margins. As you saw in our earnings release, starting with the second quarter, we now present both GAAP gross margin and adjusted gross margin. GAAP gross margin takes in depreciation charges and the cost of goods sold, whereas adjusted gross margin leaves out depreciation charges. When comparing our historically reported numbers, please keep in mind that what we historically called gross margin is now, and will from here on be called adjusted gross margin; our earnings release contains a reconciliation table to make this clear and to permit clean year-over-year comparisons. Total GAAP gross margin percentage for the second quarter of 2024 was 31.3%, an increase from 30.3% in the second quarter of 2023. Adjusted gross margin was 33.9%, against 33.4% in the second quarter of 2023. So far during 2024, we've observed solid improvements in both overtime rates and subcontractor costs within the mobile health area. In the second quarter of 2024, subcontracted labor represented 24% of total labor costs, compared with 21% in the second quarter of 2023. The rise we saw compared with the prior year came mostly from the migrant-related projects, and those projects usually involve a larger share of subcontracted labor than our core mobile health projects do. That said, subcontracted labor has come down quarter over quarter since it reached a peak in the fourth quarter of last year, when it exceeded 30% of total labor costs, and we anticipate that it will keep falling through the rest of 2024. In the second quarter of 2024, overtime represented 6.7% of total hours worked, versus 9% in the second quarter of 2023. For each of the last four quarters, overtime hours have made up a smaller percentage of total hours. There is still a bit of room to improve further, but we are nearing our goal of 5% of total hours worked. Adjusted gross margin for the mobile health segment came to 35.9% during the second quarter of 2024, up from 34.9% in the second quarter of 2023. Since the third quarter of 2023 — a period hurt by substantial costs tied to launching and ramping up the migrant programs — adjusted gross margins for the mobile health segment have risen for three quarters in a row. In the transportation segment, adjusted gross margins stood at 29.1% in Q2, lower than 30.7% in Q2 of 2023. Transportation margins in Q2 took a hit from higher subcontractor costs in one of our markets, because we could not hire fast enough to match the timing of higher volumes from certain customers. Even so, looking forward, we expect transportation gross margins to strengthen from the current level in Q3 and beyond, notwithstanding some expected wage pressure in certain geographies given that the market for EMTs is still tight, and they ought to return above 30%, as they were for the 4 quarters before Q2. Turning to operating costs, SG&A as a percentage of total revenues was 27.7% in the second quarter of 2024, far below the 32.1% recorded in the second quarter of 2023; during Q1 we carried out a targeted reduction in force, producing some cost savings that came through in Q2. In the second quarter we made major progress toward our aim of strengthening our balance sheet. At June 30, 2024, total cash and cash equivalents, including restricted cash, came to $85.8 million, versus $58.9 million at the close of the first quarter of 2024, and also above the $72.2 million on our balance sheet at the end of 2023. Strong collections in the second quarter drove the cash increase, and that also brought our accounts receivable down relative to both the amounts at the close of the first quarter and the levels at the end of 2023. Take our work with the New York City Department of Housing, Preservation, and Development — HPD — as one example. As of right now, we've gathered over 99% of the year-end 2023 accounts receivable tied to that project, and the city partners have given us assurances that payment will come for the services delivered under the contract's terms. When the quarter closed, roughly $185 million of accounts receivable sat on our books from the different migrant programs, making up about 72% of total company AR. Compare that with $210 million owed from those same migrant programs at the close of Q1, which was about 75% of total AR. Our day sales outstanding, or DSO, figured on trailing 12-month revenues, stood at 127 days when Q2 ended — an improvement from 147 days when Q1 ended, yet still above the 96-day sales outstanding recorded at this same point a year ago, before the migrant-related programs, naturally, scaled up. With those migrant-related programs set to keep winding down across the back half of 2024, we expect a substantial boost to our balance sheet as this AR gets collected and our DSO moves closer to historical norms, which should lift cash flow from operations. Beyond working capital needs, we also put cash balances to work in Q2 by carrying out our stock buyback program. Roughly 1.4 million shares were repurchased that quarter for an aggregate of about $4.9 million. So far this year, buybacks have cost us around $10 million, and we've just authorized a fresh repurchase program running through year-end for as much as $26 million — roughly what was left under the earlier authorization, which lapsed on July 30, 2024.

Lee Bienstock

executive
#4

During the previous quarter's earnings call, we noted that we anticipate a sequential decline in revenue tied to migrants for the rest of this year, because specific migrant projects are steadily winding down. That said, we anticipate that the receivables I just referred to being collected will drive further gains in our working capital. As older and larger invoices get paid, and as money going out declines consistent with reduced spending on migrant projects, we anticipate our cash balance continuing to rise over time. That said, when exactly these sizable cash inflows will arrive is still not something we can forecast. Predicting our cash inflows and cash balances month by month, or even quarter by quarter, is hard, but we now anticipate producing $80 million-$90 million of cash flow from operations during 2024, an increase of $10 million relative to the range we provided a quarter ago. Since we produced $26 million of cash flow from operations during the first half of 2024, that means we're looking at another $54 million-$64 million of cash flow from operations during the back half of this year, largely propelled by collecting our sizable municipal invoices. With that, I'd like to hand the call back to the operator so we can begin our Q&A session. Operator, please go ahead.

Gabrielle Ingoglia

analyst
#5

Hi, Gabie Ingoglia here, filling in for Sarah. I've got a quick question — could you go deeper on what's behind what you called a flurry of recent contract wins? Is what's driving that tied to the end market, or is it more about internal company strategies?

Lee Bienstock

executive
#6

Sure. Hi, Gabby. Honestly, it's a mix of both. To start, the marketplace keeps embracing in-home care more and more — bringing care to wherever patients need it, and reaching patients who lack access to good care or are drifters. So hospital systems and our insurance partners have shown strong interest in delivering care to those members, to those patients. That's definitely something we're seeing. Beyond that, we're seeing the ROI from our programs and the pilots we run alongside our insurance partners, where we've succeeded at cutting hospital readmissions and ER readmissions; and as we told one of our longest standing partners, we managed to cut those hospital readmissions by 50%, which is very significant, right? So when we can keep patients out of the hospital, that saves health plans money, and it saves hospital systems money too, since they get penalized on quality and other metrics when patients bounce back to the hospitals after being discharged. And of course, most importantly, patients don't wanna be in the hospital. They wanna be happy at home; so we've truly seen strong market adoption, and our programs are working as well. We're expanding our programs. We're adding more and more clinical offerings to those programs. We're adding more geographies, and that's helping us sign additional contracts.

Gabrielle Ingoglia

analyst
#7

All right, that's fantastic. Thanks so much, everyone.

Michael Latimore

analyst
#8

Excellent. Yeah, I appreciate it. So, I'm wondering — during the quarter, did your core business expand by more than 30% compared with the same period last year?

Lee Bienstock

executive
#9

When you compare quarter to quarter, the core business did not achieve 30% growth. Sequentially, that segment was basically level; we have a very strong expectation that it will expand as we move through the year, particularly in the latter half, once all of those fresh agreements and initiatives begin reaching their peak and start scaling up.

Michael Latimore

analyst
#10

Mm-hmm.

Lee Bienstock

executive
#11

The core business stayed pretty steady from one quarter to the next. We've got programs ramping up in the core business, and now that's happening in the back half of the year.

Michael Latimore

analyst
#12

Right, so when you mention quarter-over-quarter, do you mean sequential growth or growth compared with the same period a year ago?

Lee Bienstock

executive
#13

Sequential — comparing Q1 with Q2.

Michael Latimore

analyst
#14

All right. So my understanding is that the aim involves expanding the business by 30% year over year in the coming year, and I believe you mentioned mobile transport rising 15% year over year. Therefore, are you anticipating that mobile transport will speed up to 30% or more in the next year?

Lee Bienstock

executive
#15

Regarding mobile transport, our expectation is growth within that 15%-20% range, particularly for transport.

Michael Latimore

analyst
#16

Yeah.

Lee Bienstock

executive
#17

As we've mentioned, up to this point, transportation during 2024 has increased 13% for the year so far. That's consistent with expectations, and several expansions are set to occur during the latter half of the year within transportation. Then, naturally, those will keep growing as we head into the following year as we-

Michael Latimore

analyst
#18

Mm-hmm.

Lee Bienstock

executive
#19

We're gaining an increasing amount of work in transport, which we just told you about — in fact, we picked up several fresh transport contracts in Dover, Delaware, New Jersey, plus additional markets; therefore, our expectation is that medical transportation keeps expanding somewhere in the 15%, maybe reaching as high as 20%, heading into next year; when it comes to mobile health, growth there looks even bigger, especially since we're directing our focus toward growing our earliest customers across insurance and provider sectors, and also among hospital systems, for transitional care, social determinants of health, and other metrics tied to closing in-home care gaps. Also in the coming year, we expect considerable expansion in both our primary care service and our remote patient monitoring service. So every agreement we are in the process of signing, have already signed, or are currently extending through the remainder of this year will clearly drive momentum going into 2025 too.

Michael Latimore

analyst
#20

Mm-hmm. And it sure looks like your business is going to branch out pretty substantially. Do you have any idea how many accounts — say, those above 10% — you might have next year?

Lee Bienstock

executive
#21

If we were to make a forecast today, I'd guess fewer than 5 accounts would account for over 10% of total revenue — roughly that ballpark; but yes, and like you mentioned, that's something we're heavily focused on. We're aiming to broaden who we serve. We're looking to add more and more accounts that can eventually scale into really major accounts. And as those accounts scale up, no single account or pair of accounts creates, you know, meaningful concentration for us. That's definitely a piece of our plan.

Michael Latimore

analyst
#22

Yeah. Very good. Thanks so much.

Lee Bienstock

executive
#23

Absolutely.

David Larsen

analyst
#24

Hey, could you expand a bit more on what you're expecting for fiscal 2025 revenue — that $400 million figure, I believe? From what I heard you say, it seems like the actual number might exceed $400 million should some New York City migrant revenue be included. Then, regarding the mobile health piece within that $400 million, I believe we discussed it being around $175 million, with $50 million of that originating from payers. Could you elaborate a bit more on that payer portion? For instance, that $50 million — how does it stack up against what you'd anticipate for fiscal 2024, and what are its various components? Thanks a lot. I appreciate it.

Lee Bienstock

executive
#25

Of course, Dave. Great to hear from you; so as you pointed out, for 2025, our expectation for the base business is $400 million; and we don't anticipate that some of the wraparound migrant revenues will carry over into the following year, such as the security and some of the wraparound services we had been delivering on an emergency basis. What we do believe will possibly stretch into next year on the migrant side, which would bring in additional revenue, is especially the clinical services and the population health services, along with the infectious disease control, the screening, the behavioral health care, the depression screening, and all that medical expertise that might continue into next year. And that's truly what we're planning for. But the $400 million in the base business is really made up of the revenues we anticipate in the hospital systems, in both hospital systems, both transitions of care and medical transportation for the hospital systems, municipal programs, population health programs, with municipalities and with our payer vertical. As you noted, the payer vertical, we're projecting it to be $50 million of that revenue next year; that's going to originate from three revenue streams. The first revenue stream is going to be the care gap closures we're carrying out in the home. For each care gap closed, we collect a rate that's negotiated with the payers, and so we're scaling that up significantly. We shared — we've doubled the number of patients at the top of the funnel quarter-over-quarter. So from Q1 to Q2 of this year, we've doubled the number of patients that our health plan partners have assigned to us. So that's a really good harbinger for the opportunity in front of us as we move through this year and into next. And we also have a number of opportunities in the pipeline that are going to come to fruition in the back half of this year and into next year; so one of those revenue streams with the payers is going to be the care gap closures. There's also a chance for us, with the patients being assigned to us, to step in as their primary care provider and set up a capitated rate for ourselves as part of serving as their primary care provider, so that becomes revenue stream number two. Then the third one, through the payer vertical, involves the patients we monitor. As we told you last quarter, 50,000 patients are being monitored by us right now, and we anticipate that figure reaching 70,000 patients in the coming year. And that $50 million we're projecting for next year will be made up of all three of those revenue streams.

David Larsen

analyst
#26

That's quite useful. To me, it sounds like what you're bringing to America is basically what this nation requires. Every health plan this quarter appears to be discussing at length, you know, greater medical cost ratios, increased Medicare Advantage utilization, you know, more Medicaid utilization, you know, strain on their, you know, Medicare cost ratios. In what ways does DocGo feel that, if at all? Does it help or hurt, and for what reason?

Lee Bienstock

executive
#27

We believe we're, we believe we're a great fit for that landscape, since at the end of the day, our aim is, we're striving to deliver more proactive care, correct? So we head into the home and perform a colon cancer screening or a bone density scan or a depression screen. We're engaged in social determinants of health work. And so we enter the home, and we're going to serve those members, all with the aim of identifying chronic conditions or assisting with managing chronic conditions before they turn more acute, catastrophic, and more costly; so that truly is our value prop, and that aligns well with the environment you're describing, which is increasing costs and all of that being caused, maybe by patients who weren't receiving the care they required, maybe throughout the pandemic. Maybe they lacked solid access to care, and clearly the plans are noticing that. So we align very well with that. That's what our value prop is. We believe the investment they're making with us in fact saves them money and clearly enhances patient outcomes, which once more is what the entire system wants. So we feel like we're truly of the moment, of the time. We feel like we possess the right solution for the right need in the marketplace today, and we feel like we're capable of saving the health plans money, we're capable of saving patients heartache and helping manage their care; and then as you move through the continuum that really we're seeking to participate in, correct? We go from care gap, which once more is intended to be proactive care, to us turning into a primary care provider for those patients; now, we're boosting the care that's accessible to those drifter patients, those unattached patients, those patients who lack good primary care. You know, primary care is a very strong indicator of whether or not a patient is receiving the care they need, the proactive care they need, and the longitudinal care they need. So we play, once more, very well into that model; and then in time, the contracts we're signing do include the ability for us to take part in the value arrangements that you're describing, those Medicare Advantage arrangements that you're describing. Once we feel at ease with that, and once we feel like we genuinely are capable of affecting that patient's total cost of care and health outcomes, which once more, is where our Medical Advisory Board comes. We are going to put out studies that demonstrate exactly that, so our roadmap in this area stretches far into the future. The early signals we're seeing are quite encouraging regarding the value we deliver and the difference we make for patients. In a landscape where things may have tilted toward, you know, purely remote, purely digital approaches, we believe that model does have a place. Still, we're convinced the face-to-face piece is something we contribute. As an increasing number of AI solutions reach the market, and as a growing number of digital, digital products reach the market, we're positioned to serve as the collaborator that delivers those straight to patients inside their own houses. That makes us the final leg that assists in activating and bringing to market the technology we're developing ourselves, plus technology we can join forces on alongside other, collaborators in this field. So in short, our ambitions have us genuinely thrilled. We're quite fond of our position within the healthcare ecosystem, and we're confident we offer a great deal to this area, serving our payer partners, our hospital systems, and municipalities, yet in fact, even more crucially, serving the patients, since when patients grow healthier and healthier and receive the preventive care they require, in the end, they end up costing the system a smaller amount of money, which once more, is precisely what everyone is united around accomplishing now.

David Larsen

analyst
#28

Excellent, many thanks. I'll rejoin the line.

Lee Bienstock

executive
#29

Appreciate it, Dave.

Pito Chickering

analyst
#30

Hi there, good afternoon, everyone. I've got another bridge-related inquiry regarding margins for 2025. As I recall, you previously mentioned transport around a 33% range, alongside base level health in the high 30s, and SG&A near 23%. When you combine all of those together, does that mean we ought to be looking at 10% margins on $40 million of revenue for next year?

Norman Rosenberg

executive
#31

Hello, this is Norm. Yes, that's precisely the way we're presenting it. Over the past three months or so, nothing has shifted regarding the mechanics of that common size analysis. Our target for the EBITDA margin would be 10%. Naturally, we'd expect to exceed that. So we'd hope to see... Ideally, we'd prefer to model it at 12% to 12.5%, or even above that. But as you know, we've essentially established the floor at roughly 10%.

Pito Chickering

analyst
#32

All right. So compared with what was said three months ago, we were roughly discussing 12.5%. Has anything shifted between the prior quarter and the current one?

Norman Rosenberg

executive
#33

No.

Pito Chickering

analyst
#34

So would you say we're looking at a base of 10 and a target of 12.5?

Norman Rosenberg

executive
#35

That's right. It's identical.

Pito Chickering

analyst
#36

All right, understood. Moving to my second question. When you look at that $40 million of EBITDA for next year, leaving aside the catch-up on DSOs and the migrant programs, would you anticipate cash flow conversions to land around that figure?

Norman Rosenberg

executive
#37

Sure. Setting aside the catch-up on DSOs is a bit tough. In 2024, it's such a significant element, but our thinking is that the bulk of it gets finished by the close of this year, though I'll admit I do believe some catch-up will occur in Q1 of next year as our DSOs move more into line. But setting that to one side; on that $40 million of EBITDA, I'd say, you know, we would normally be in a position to extract perhaps $30 million in cash flow, correct? You've got some tax to pay, you have some other, well, perhaps some interest expense in there too; so I'd say it ought to convert fairly well.

Pito Chickering

analyst
#38

All right, and that brings us to the final question. Have any mobile health clients been lost by you during this year? And when you consider the customer base from 2021 and 2022, what percentage of them have broadened the scope of what they do with you? Thanks a lot.

Lee Bienstock

executive
#39

Sure thing; so we did in fact announce some launches — we brought out several new payers during this year. We also told everyone about winning several new contracts. A contract was just secured with the State of New Mexico; mobile vaccination clinics, nursing and virtual call centers, plus additional behavioral healthcare work for the New Mexico Behavioral Health Institute are what we're delivering, so that is being launched; we also made public a partnership win with one of Arizona's biggest outpatient physician radiology groups, which carries the chance to grow into Texas and other states over the coming weeks; so those new contracts have been secured by us. They are mobilizing and launching at this very moment; on top of those municipal contracts, several payer contracts that are growing have also been won by us. Nearly every one of the payer contracts we have mobilized at present has grown across this year. And a very big share, a substantial share, of our hospital system contracts are growing with us too, throughout the year. So we keep growing the customers that we have. I believe you're seeing us sign new customers as well and put a great deal of emphasis there while we free up resources from the migrant-related projects that clearly ate up a lot of resources across the last year; and at this point those resources are being freed up so we can launch with freshly signed contracts, and that is precisely what we are doing.

Pito Chickering

analyst
#40

Great. Thanks so much.

David Grossman

analyst
#41

Hello there, good afternoon, and thank you. To kick things off, Norm, I have a couple of fast questions for you. I apologize — I'm at an airport right now, so forgive me if the filing already covers this, but it appears that transport margins came in fairly thin on the EBITDA line, possibly around break-even. Is that an accurate read? And assuming it is, aside from subcontractor costs, is there anything else you'd point to that affected those margins?

Norman Rosenberg

executive
#42

Sure. Yeah, let's talk about that. It really was all contained within the margin piece, but that was a pretty big delta. When it comes to transport, the margin for the quarter came in at 29.1%, as we noted earlier. That's roughly four to five points below the levels we've been seeing recently. A few things are behind this. In that one specific market we talked about, the subcontractors will still play a role, though a far smaller one during Q3, and by the latter part of Q3, that factor goes away entirely. The second item involves a workers' comp premium adjustment tied back to 2021, from the period when we were covered by the New York State Insurance Fund in New York. These days we're self-insured. Due to various circumstances, their work tied to our planned year of 2021 wasn't finished until just these past few weeks. Roughly $2 million represented the total premium adjustment stemming from that period three years back. Breaking it down, a portion relates to mobile health while another portion involves transport — and transport likely accounts for 2 points of margin. So when I combine those two elements, meaning the old insurance adjustment that won't recur plus the subcontractors, my estimate is that somewhere in the range of 4 to 4.5 points of gross margin was lost. Taken together, then, you're looking at around 4 points. That hit the business to the tune of more than a million dollars, easy.

David Grossman

analyst
#43

Understood. Now, turning briefly to free cash flow—I was running the numbers in my head based on what you disclosed regarding the buyback, and there were likely other items factored in as well. That said, did the underlying operations produce positive cash flow before working capital changes during the quarter?

Norman Rosenberg

executive
#44

Indeed, they did. And as you're aware, the cash flow statement has been made available. So you would—yes, you'd have observed a favorable figure from what we refer to as P&L cash flow too. That said, clearly, during this period we benefited from, well, from additional elements stemming from the business itself.

David Grossman

analyst
#45

Understood. And finally, one for you, Lee. You mentioned sequentially doubling the assigned lives. Could you help us understand how that translates into revenue across the coming months? And how should we read that statistic from a P&L perspective?

Lee Bienstock

executive
#46

Sure. That doubling of lives assigned to us sits at the top of the funnel. That's the metric we're really focused on initially. What happens is those assigned lives will progress toward and through the funnel; we'll visit those patients at home; we'll close their care gaps. Sometimes we'll close several care gaps, and revenue will begin to be generated from those care gaps closed. Meanwhile, we're also going to keep adding to the top of the funnel. But as those patients progress through the funnel, we'll close those care gaps. Some portion of those lists will lead to visits from us. Some portion of those patients will stay unengaged, regardless of how much or how convenient our services are. But we've been quite successful to date engaging unengaged, unattached patients, so a percentage of the list. It's too early at this point for us to publish and post what the conversion rate is from the top of the funnel into care gap closure. But at this point, our partners are very pleased with what we've managed to achieve on the conversion rate; but revenue will be generated and is being generated from the care gaps that are closed, and that will occur. It is occurring now. It'll occur more in Q3. It'll occur more in Q4, that's our plan. Then once we can close those care gaps, then we can convert some of those patients, again, another percentage of those patients, into primary care patients for our PCP practice. And then we'll be able to bill fee for service and ultimately a capitated rate for those patients; that will occur later in the year and more so into 2025; but the initial metric after the top of the funnel is the number of patients we can close care gaps for. And then again, later in the year and into next year, they'll convert over into PCP patients for, again, another revenue stream; we won't risk share or value-based arrangements with these partners, even though they are included. The ability to do so is included in the contract; that won't occur until next year, and that's sort of further down the funnel.

Norman Rosenberg

executive
#47

Right. Dave, to return to what you asked earlier and give it a concrete figure — we did include the cash flow statement for the six months, and beyond that, we separated out the three-month Q2 figure. Operating cash flow for Q2 came to roughly $37 million. My estimate is that around one-third of it originated from the business as such — meaning net income plus the addition of all non-cash expenses. The remaining roughly two-thirds came from movements in the working capital line items; so approximately 24 of that against 12, and those together produced $36-$37 million for the quarter.

David Grossman

analyst
#48

Understood. That's clear. Very well, everyone. I appreciate it a lot.

Lee Bienstock

executive
#49

Thank you, Dave.

Norman Rosenberg

executive
#50

Sure.

Matt Shea

analyst
#51

Yeah, hey, this is Matt Shea, covering for Ryan. Appreciate you taking my questions. I'd like to go further into care gap closure. It's really encouraging to see that figure double, but I'm wondering what portion of that resulted from newly signed payer relationships as opposed to growing the ones you already have? Also, thinking about the second half of the year, given that payers are feeling pressure around star ratings and medical costs, could your current payer partners provide you with additional patient lists to go after, on top of the first ones? And if that's the case, does the guidance you've given already account for it?

Lee Bienstock

executive
#52

Yes and yes. Matt, thanks for the question — good to hear from you. Regarding closing care gaps: the jump between Q1 and Q2, that doubling, had two sources. Part of it was growing with partners already on board. But we also brought a new partner under contract, and just the roster they handed us was enough on its own to double the figure — a really big payer we'd been pursuing, now signed and in the process of getting up and running as we speak. So yes, existing customers gave us added expansion, and a newly signed, very large payer essentially delivered the doubling. And then when we get to the second half of the year, we actually are seeing some momentum building there as plans work to finish closing out care gaps, as they turn to their partners wanting more speed, as they aim to reach the maximum number of patients possible before the year wraps up. That momentum is real in our view; we believe it will act as a catalyst for the business during that latter part of the year, and we're building our plans around it. At this moment we're adding capacity to support it across every market where we operate, and our expectation is that it becomes a tailwind in the second half. Without question.

Matt Shea

analyst
#53

Great. That's good to know. And I believe both last quarter and this one, it seems as though health system partners are attaching mobile health to transport agreements, or at minimum expanding their mobile health initiatives. I'm wondering how much untapped room exists for you to pursue in mobile health among health systems. Is there a way to consider penetration rate or the size of the opportunity, and are you taking the place of incumbent vendors, or do these tend to be more greenfield situations?

Lee Bienstock

executive
#54

At this point, we've only begun to tap into what's possible with mobile health across our hospital systems. Our position is strong since we've spent years collaborating closely with hospital systems on medical transportation. We've earned their trust as a partner, built tight relationships, and now we're using those connections to serve other areas of the hospital — providing patient monitoring for hospital systems in cardiology, and also handling transitions of care. When it comes to cardiac monitoring, we're generally pushing out the service providers already in use. Cardiac monitoring is an established practice, and our offering stands out because our adherence typically sits around 90%. We've demonstrated patient adherence rates of 90%, whereas competitors generally land near 60%. That's how we've been able to make sales, and we've been drawing on our hospital system customers and relationships to roll out our cardiac monitoring product. We plan to put significantly more investment there over the course of this year and into the next, and that's already underway. As for transitions of care, I believe providers already exist serving that area today, so we're going head-to-head with some of them. Even so, there's still quite a bit of open territory. Hospital systems are beginning to understand that mobile health programs can be deployed for lower acuity care delivered at home after discharge, aiming to reduce patient readmissions. Plenty of services and preventive work can happen at home following discharge, so the patient doesn't need to return to the hospital system or potentially receive no visit at all, only to end up bouncing back. That's the value proposition. I believe untapped room exists there. Competition is present in that area, and we're directing increasingly more resources toward it so we can attempt to capture as much of that open territory as possible, especially as momentum keeps building with the hospital systems.

Matt Shea

analyst
#55

Thank you. I appreciate you taking the call.

John Pinney

analyst
#56

Hello, John Pinney here, filling in for Richard Close. Thanks for taking my question. So, I'll keep this brief. Are you still anticipating the base business to come in at $280 million-$300 million? Does that still break down toward the upper end, approximately $105 million for mobile health and $195 million for transportation?

Lee Bienstock

executive
#57

Yes, that remains the case. For this year, the forecast is $280 million-$300 million for the base business.

John Pinney

analyst
#58

That split you gave is very near where things stand at the moment. All right, excellent. Then I believe during the prior quarter you talked about goals of, say, 10, and for 2025, 10,000 PCP patients, 65,000 care gap closures, 70,000 remote patient monitoring. Could you perhaps offer some thoughts on, say, where you anticipate tracking in 2024 against those metrics?

Lee Bienstock

executive
#59

Yes, certainly, John. So those metrics, as you're describing them, we told everyone during the prior quarter that our projection is 65,000 care gaps closed, 10,000 PCP patients, as I noted, moving through the funnel from care gap to PCP, and then 78,000 patients monitored; we communicated during the prior quarter, we sit at 50,000 patients monitored so far; we communicated that during the prior quarter, and we'll keep communicating that figure from time to time as we're achieving more and more progress toward it, probably, as we finish 2024 moving into 2025; but we're on track toward those metrics for the coming year. We are establishing the partnerships. Either we've signed them and are rolling them out right now, or we have a large number of those partnerships in the pipeline to be signed and rolled out at the close of this year moving into the next. And so when we examine the bottoms-up projection of those figures, we either have the customers today to scale with, and we're going to be bringing on new customers to assist us in hitting those figures in the coming year.

John Pinney

analyst
#60

All right, that's great, thank you. I suppose this will be my final question. You brought up that the Medical Advisory Board is, you know, assisting with — part of what it contributes is getting clinical studies launched and running. Could that possibly have acted as an obstacle when it comes to forming more payer partnerships? Also, are there any studies you're able to discuss during this call, and what might be beneficial moving forward? Thanks.

Lee Bienstock

executive
#61

For sure. We're extremely enthusiastic about the Medical Advisory Board. You can see the members of that Medical Advisory Board by visiting our website. We take a lot of pride in the physicians we're bringing on. And honestly, the guiding principle behind the Medical Advisory Board is that, as we move further and further into primary care and specialty care, correct? We've got programs in cardiology, nephrology, endocrinology. We want to be certain we have world-class leading physicians creating the clinical programs in those specialties to complement the primary care we provide. That's because a lot of the patients we'll have in our primary care practice suffer from one or more chronic conditions tied to heart health, end-stage renal disease, diabetes, and so forth. So those physicians are now part of our company, genuinely steering the clinical programs we're going to provide and deliver for our primary care patients. So we're extremely enthusiastic about the Medical Advisory Board. One of the primary objectives, besides helping us build out those clinical offerings, will be to publish medical research and leading medical journals regarding the efficacy and the outcomes, the clinical outcomes of those mobile health programs we deliver, in order to truly demonstrate the impact we're having, but more broadly, what expanding access through mobile healthcare can accomplish in general for the wider industry. And we're leading the charge on that, so we're going to target publishing research and leading medical journals, along with publishing white papers too. It hasn't been an obstacle, but I firmly believe that with that clinical research, with those medical outcomes, we can genuinely leverage it to supercharge our pipeline and our sales efforts, since that will truly demonstrate the efficacy of the mobile health programs. We do use it currently. We do share, as I did, that the programs we're running currently are having a material impact on ED readmission avoidance, and closing care gaps and increasing HEDIS star measures for the health plans. So we do leverage those metrics and data-driven sales and data-driven business development currently. We simply believe it's going to elevate things to the next level once it's published in clinical research and is a very structured clinical study. So we use. It's not an obstacle currently; we use data to sell currently and to demonstrate the efficacy of our programs. To my mind, we have a chance to elevate that further using a highly organized clinical approach, and I'm truly enthusiastic about the Medical Advisory Board taking that on. In fact, just last week we held our very first in-person gathering with the Medical Advisory Board, and it's genuinely thrilling to see the individuals who are now affiliated with our company. For an organization at our stage in this space, you'd be hard-pressed to find a more distinguished Medical Advisory Board.

John Pinney

analyst
#62

Great. Thanks, guys.

Lee Bienstock

executive
#63

Thank you so much. I wanna thank everybody for joining us, and hope to speak to you soon. Be well.

Operator

operator
#64

That brings the DocGo Q2 2024 earnings conference call to a close. At this point you're free to hang up, and have a wonderful day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.